Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Allogeneic fecal microbiota transplantation to prevent graft-versus-host disease after allo-HSCT
2020-000673-24Phase 2Active
- Sponsor
- Centre Hospitalier Universitaire de Clermont-Ferrand
- Start
- Oct 2020
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of allogeneic fecal microbiota in graft-versus-host disease (GVHD) (2 arms), sponsored by Centre Hospitalier Universitaire de Clermont-Ferrand. Primary endpoint: Graft-versus-host disease-free, relapse-free survival. Started Oct 2020; status: active.
02
Drugs
allogeneic fecal microbiota
03
Conditions
graft-versus-host disease (GVHD)
Beyond the preview
Go deeper on 2020-000673-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-000673-24.